Navigating the Uncertainty of Telehealth

Navigating the Uncertainty of Telehealth

The future of telehealth does, in fact, appear to be murky.

Is telehealth experiencing a post-COVID-19 hangover? That’s how one healthcare executive recently labeled the troubles currently facing the industry. Citing an increasingly pessimistic legal, legislative, and regulatory environment surrounding digital health, the coming months might serve as an inflection point for the industry – and many believe that only the strong will survive.

Recently, the U.S. Drug Enforcement Administration (DEA) released proposed permanent telemedicine rules about the prescription of controlled medications that are a sharp turnaround from pandemic-era freedoms. The DEA stated that the rules would be adding safeguards to situations in which controlled medications might have been overprescribed. As you may recall, the pandemic saw a suspension of the Ryan Haight Online Pharmacy Consumer Protection Act: the federal statute that generally requires at least one in-person consultation before prescribing controlled substances. 

The new proposed rules reinstitute the provisions of the Act for Schedule II medications, while authorizing just one 30-day prescription refill via telehealth for Schedule III, IV, or V medications before an in-person consultation is required. If passed, this rule means that for consumers who began treatment during the pandemic under the suspension and have never seen a provider in person, they suddenly have a maximum of 180 days to find a local provider and be seen.

Telehealth providers and advocates are, to put it simply, not pleased. A senior VP for the American Telemedicine Association stated that this would “sever” the continuity of care for countless Americans. Many have called the rules overly complex and more restrictive than necessary, and a telehealth company CEO stated that the rules were sending patients “back into the dark ages of care delivery.”

The Biden Administration, however, has a different outlook on the proposed rules. U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra stated that the new proposed rules are far more lenient than pre-pandemic rules, and noted that the rules have exceptions for opioid use disorder treatment medications. The text of the proposed rule itself notes that the impetus behind the Ryan Haight Act itself is still a key public health concern: The Act wanted to combat easy Internet access and a lack of medical supervision (and this hasn’t changed). 

This is coming at a time in which the economic market for digital health is looking unclear. The tech industry in general has been hit with near-constant layoffs, and companies’ digital health teams were often the first to go.

Most recently, Alphabet (the parent company of Google) and Amazon announced that they would end many digital healthcare projects and lay off employees, citing an uncertain economy and restructuring. Silicon Valley Bank, which collapsed just last week, partnered with nearly half of the venture-backed healthcare and tech companies. High interest rates are impacting investment in the field itself overall. 

And as you may recall, several telehealth companies have seen legal trouble for selling consumer information to third-party advertisers. Indeed, just since my last report on the issue, telepsychiatry giant BetterHelp was fined nearly $8 million for the practice, and Cerebral, still under investigation by the U.S. Department of Justice (DOJ), sent out notices to over 3 million consumers that it had disclosed HIPAA-protected personal health information (PHI) to third-party platforms.

All of this news can seem daunting, especially when so many people can agree that telehealth is a vital part of healthcare delivery. But this might be a necessary evil coming out of the relative total freedom of the pandemic era.

As some have pointed out, this new guidance is at least clearing the path forwards and providing a defined shape for the future of telehealth – and public comment may modify this shape before the rules become permanent.

What is clear is that every practice will need to adapt to a new landscape, and hospitals, providers, and consumers alike will have the opportunity to choose what works for them and what companies meet their needs…and what doesn’t.

Facebook
Twitter
LinkedIn

Cate Brantley, JD

Cate Brantley is a Senior Government Affairs Liaison for Zelis. She has over 9 years of experience in both the public and private sector. Cate is licensed to practice law in the state of Oklahoma.

Related Stories

Leave a Reply

Please log in to your account to comment on this article.

Featured Webcasts

2026 IPPS Masterclass 3: Master MS-DRG Shifts and NTAPs

2026 IPPS Masterclass Day 3: MS-DRG Shifts and NTAPs

This third session in our 2026 IPPS Masterclass will feature a review of FY26 changes to the MS-DRG methodology and new technology add-on payments (NTAPs), presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.

August 14, 2025
2026 IPPS Masterclass Day 2: Master ICD-10-PCS Changes

2026 IPPS Masterclass Day 2: Master ICD-10-PCS Changes

This second session in our 2026 IPPS Masterclass will feature a review the FY26 changes to ICD-10-PCS codes. This information will be presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.

August 13, 2025
2026 IPPS Masterclass 1: Master ICD-10-CM Changes

2026 IPPS Masterclass Day 1: Master ICD-10-CM Changes

This first session in our 2026 IPPS Masterclass will feature an in-depth explanation of FY26 changes to ICD-10-CM codes and guidelines, CCs/MCCs, and revisions to the MCE, presented by presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.

August 12, 2025

Trending News

Featured Webcasts

The Two-Midnight Rule: New Challenges, Proven Strategies

The Two-Midnight Rule: New Challenges, Proven Strategies

RACmonitor is proud to welcome back Dr. Ronald Hirsch, one of his most requested webcasts. In this highly anticipated session, Dr. Hirsch will break down the complex Two Midnight Rule Medicare regulations, translating them into clear, actionable guidance. He’ll walk you through the basics of the rule, offer expert interpretation, and apply the rule to real-world clinical scenarios—so you leave with greater clarity, confidence, and the tools to ensure compliance.

June 19, 2025
Open Door Forum Webcast Series

Open Door Forum Webcast Series

Bring your questions and join the conversation during this open forum series, live every Wednesday at 10 a.m. EST from June 11–July 30. Hosted by Chuck Buck, these fast-paced 30-minute sessions connect you directly with top healthcare experts tackling today’s most urgent compliance and policy issues.

June 11, 2025
Open Door Forum: The Changing Face of Addiction: Coding, Compliance & Care

Open Door Forum: The Changing Face of Addiction: Coding, Compliance & Care

Substance abuse is everywhere. It’s a complicated diagnosis with wide-ranging implications well beyond acute care. The face of addiction continues to change so it’s important to remember not just the addict but the spectrum of extended victims and the other social determinants and legal ramifications. Join John K. Hall, MD, JD, MBA, FCLM, FRCPC, for a critical Q&A on navigating substance abuse in 2025.  Register today and be a part of the conversation!

July 16, 2025

Trending News

Happy National Doctor’s Day! Learn how to get a complimentary webcast on ‘Decoding Social Admissions’ as a token of our heartfelt appreciation! Click here to learn more →

CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24